Advertisement
UK markets closed

  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     

  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     

  • AIM

    779.67
    +6.64 (+0.86%)
     

  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     

  • Bitcoin GBP

    53,611.08
    +1,412.21 (+2.71%)
     

  • CMC Crypto 200

    1,392.53
    +61.92 (+4.65%)
     

  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     

  • DOW

    40,589.34
    +654.27 (+1.64%)
     

  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     

  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     

  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     

  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     

  • DAX

    18,417.55
    +118.83 (+0.65%)
     

  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     
PROPERTY:

8 champion homes in Olympic host cities

A selection of properties in former Games cities as Paris 2024 starts

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

Immunocore Holdings Limited
·2-min read
Immunocore Holdings Limited
Immunocore Holdings Limited

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that management will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled for Wednesday, January 11, 2023, at 9:00 a.m. Pacific Standard Time (PST).

ADVERTISEMENT

The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT:

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com